A carregar...

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

S9788 is a new triazineaminopiperidine derivate capable of reversing multidrug resistance (MDR) in cells resistant to chemotherapeutic agents such as doxorubicin. It does not belong to a known class of MDR revertants, but its action involves the binding of P-glycoprotein. Thirty-eight evaluable pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Punt, C. J., Voest, E. E., Tueni, E., Van Oosterom, A. T., Backx, A., De Mulder, P. H., Hecquet, B., Lucas, C., Gerard, B., Bleiberg, H.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1997
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2228136/
https://ncbi.nlm.nih.gov/pubmed/9374386
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!